Tamtaji et al. argued that probiotic treatment resulted in a significant decrease in the Movement Disorder Society-Unified Parkinson Disease Rating Score (MDS-UPDRS) and a reduction of systemic inflammation (assessed by high-sensitivity C-reactive protein) and oxidative stress (assessed by malondialdehyde and enhanced glutathione) compared with placebo treatment [32]. The gene discussed is CRP; the disease is movement disorder.